Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
I have been working for Zenopa in the dental Industry for more then two years. All through the period my Contractor Manager has provided me with the utmost support and guidance with expenses.
Pamela, 2012

Pfizer reports positive data from real-world Xiapex analysis

25 June 2012 11:18 in Pharmaceutical Company Product News


Pfizer has reported positive real-world data for Xiapex, its approved treatment for Dupuytren's contracture.

Information taken from real-life clinical practices has shown that Xiapex is able to deliver an improved range of movement to Dupuytren's contracture patients, affirming the conclusions of the clinical study Cord I.

It was also demonstrated that these positive treatment outcomes can be delivered via fewer injections and hospital visits than was thought to be the case following the phase III trials.

Meanwhile, analysis of recurrence data conducted during a separate study showed that treatment response to Xiapex can be maintained at three years.

Dr Gary Pess, an orthopaedic surgeon at the Drexel University School of Medicine in Philadelphia and the Central Jersey Hand Surgery, said: "This could potentially lead to a positive impact on healthcare costs associated with Dupuytren's contracture treatment in some countries."

Last week, the company reported positive data from a phase III study of the lung cancer drug Xalkori, showing the safety and efficacy of the treatment.ADNFCR-8000103-ID-801392146-ADNFCR

Other news stories from 25/06/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd